Paper19587342
Clinical practice. Screening for ovarian cancer.
Clarke-Pearson DL. N Engl J Med, 2009. Cited by 263 papers, by iCite.
Cite this record
ConductScience Library. Clinical practice. Screening for ovarian cancer. Papers, record 19587342. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19587342
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biomarkers, Tumor | Major topic |
| Ovarian Neoplasms | Major topic |
| Ovary | Major topic |
| CA-125 Antigen | |
| Early Detection of Cancer | |
| Female | |
| Humans | |
| Mass Screening | |
| Middle Aged | |
| Practice Guidelines as Topic | |
| Risk Factors | |
| Ultrasonography |
Source PubMed
Cited by147
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 263 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42088998 | Clinical Features of Malignant Ovarian Germ Cell Tumors According to Demographic and Pathologic Characteristics. | Health Sci Rep | 2026 | https://conductscience.org/library/papers/42088998 | PubMed |
| 41983061 | Circulating extracellular vesicle DNA (EV-DNA) and cell-free DNA in ovarian cancer: pathological relevance and diagnostic applications. | Extracell Vesicles Circ Nucl Acids | 2026 | https://conductscience.org/library/papers/41983061 | PubMed |
| 41588542 | Development and validation of gene expression-based signature for high-grade serous ovarian cancer. | J Ovarian Res | 2026 | https://conductscience.org/library/papers/41588542 | PubMed |
| 41193397 | Unmet needs and emerging therapeutics in low-grade serous ovarian carcinoma: from chemoresistance to precision medicine. | Future Oncol | 2025 | https://conductscience.org/library/papers/41193397 | PubMed |
| 40941707 | Diagnostic Value of Simple Ultrasound Features and Inflammatory Markers in Postmenopausal Ovarian Cysts. | Diagnostics (Basel) | 2025 | https://conductscience.org/library/papers/40941707 | PubMed |
| 40521356 | Association between dietary vitamin intake and all-cause mortality in ovarian cancer patients: a prospective cohort study. | Front Nutr | 2025 | https://conductscience.org/library/papers/40521356 | PubMed |
| 40002854 | Integrative Analysis of Gene Expression and Promoter Methylation to Differentiate High-Grade Serous Ovarian Cancer from Benign Tumors. | Biomedicines | 2025 | https://conductscience.org/library/papers/40002854 | PubMed |
| 39790752 | Histopathological spectrum of ovarian tumors in Jharkhand, India: A retrospective study. | J Family Med Prim Care | 2024 | https://conductscience.org/library/papers/39790752 | PubMed |
| 39456397 | Protective Effects of Nettle Tea on SKOV-3 Ovarian Cancer Cells Through ROS Production, Apoptosis Induction, and Motility Inhibition Without Altering Autophagy. | Foods | 2024 | https://conductscience.org/library/papers/39456397 | PubMed |
| 39185248 | Dual-modal Photoacoustic and Ultrasound Imaging: from preclinical to clinical applications. | Front Photon | 2024 | https://conductscience.org/library/papers/39185248 | PubMed |
| 38542081 | Constitutional BRCA1 and MGMT Methylation Are Significant Risk Factors for Triple-Negative Breast Cancer and High-Grade Serous Ovarian Cancer in Saudi Women. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38542081 | PubMed |
| 38193139 | The High Sensitivity of the Multi-Cancer Detection Test ONCOVERYX-F Offers a Promising Platform for Ovarian Cancer Screening. | Int J Womens Health | 2024 | https://conductscience.org/library/papers/38193139 | PubMed |
| 37674925 | Epidemiology and risk factors for ovarian cancer. | Prz Menopauzalny | 2023 | https://conductscience.org/library/papers/37674925 | PubMed |
| 37533954 | Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria. | Ecancermedicalscience | 2023 | https://conductscience.org/library/papers/37533954 | PubMed |
| 37370973 | Advantages and Limitations of Ultrasound as a Screening Test for Ovarian Cancer. | Diagnostics (Basel) | 2023 | https://conductscience.org/library/papers/37370973 | PubMed |
| 37168255 | Stratification of ovarian cancer borderline from high-grade serous carcinoma patients by quantitative serum NMR spectroscopy of metabolites, lipoproteins, and inflammatory markers. | Front Mol Biosci | 2023 | https://conductscience.org/library/papers/37168255 | PubMed |
| 36950209 | Osteopontin as a Tumor Marker in Ovarian Cancer. | J Midlife Health | 2022 | https://conductscience.org/library/papers/36950209 | PubMed |
| 36765618 | Changes in Nucleolin Expression during Malignant Transformation Leading to Ovarian High-Grade Serous Carcinoma. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36765618 | PubMed |
| 36721593 | The Histopathological Patterns of Ovarian Neoplasms in Different Age Groups: A Retrospective Study in a Tertiary Care Center. | Cureus | 2022 | https://conductscience.org/library/papers/36721593 | PubMed |
| 36449939 | Impact of proper surgical treatment on the survival of patients with epithelial ovary cancer. | Rev Col Bras Cir | 2022 | https://conductscience.org/library/papers/36449939 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19587342
GET https://conductscience.org/api/papers/v1/19587342/cited_by?page=2